Clinical Trial Update: Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease [Phase 1, Phase 2]

View source ↗

Summary

Open-label study of isotretinoin in mild to moderate Alzheimer's disease was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ISOTRETINOIN (Isotretinoin)

Snippet

Sponsor: University Hospitals Cleveland Medical Center | Conditions: Alzheimer's Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-06-15